Patents by Inventor Nicholas C. Smith

Nicholas C. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids encoding recombinant 56 and 82 kDa antigens from gametocytes of and their uses
    Patent number: 7968695
    Abstract: The present invention provides the recombinant cloning and sequencing of two of the major Eimeria maxima gametocyte antigens having molecular weights of 56 and 82 kDa and the expression of these recombinant antigens in an E. coli expression system using the plasmid pTrcHis. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen. The subject invention also provides two 30 kDa proteins and three 14 kDa proteins from Eimeria maxima gametocytes having at the N-terminal end the amino acid sequence described herein. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen and any of the aforementioned proteins.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: June 28, 2011
    Assignee: Abic Biological Laboratories Ltd.
    Inventors: Sabina I. Belli, Nicholas C. Smith, Michael Wallach
  • Nucleic acids encoding recombinant 56 and 82 kDa antigents from gametocytes of Eimeria maxima and their uses
    Publication number: 20090196888
    Abstract: The present invention provides the recombinant cloning and sequencing of two of the major Eimeria maxima gametocyte antigens having molecular weights of 56 and 82 kDa and the expression of these recombinant antigens in an E. coli expression system using the plasmid pTrcHis. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen. The subject invention also provides two 30 kDa proteins and three 14 kDa proteins from Eimeria maxima gametocytes having at the N-terminal end the amino acid sequence described herein. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen and any of the aforementioned proteins.
    Type: Application
    Filed: May 30, 2008
    Publication date: August 6, 2009
    Inventors: Sabina I. Belli, Nicholas C. Smith, Michael Wallach
  • Nucleic acids encoding a recombinant 250 kDa antigen from sporozoites/merozoites of and their uses
    Patent number: 7462707
    Abstract: The present invention provides an isolated nucleic acid comprising a nucleotide sequence encoding a 250 kDa polypeptide from Sporozoites/Merozoites of Eimeria maxima, or encoding a homolog of the polypeptide, or a complement of the nucleic acid and a method of producing a recombinant 250 kDa polypeptide of the same. The present invention also provides an isolated nucleic acid comprising a nucleotide sequence encoding an immunodominant portion of a 250 kDa polypeptide from Sporozoites/Merozoites of Eimeria maxima having the amino acid sequence described herein, or encoding a homolog of the polypeptide, or a complement of the nucleic acid.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: December 9, 2008
    Assignees: University of Technology, Sydney, Abic Biological Laboratories Teva, Ltd.
    Inventors: David Witcombe, Nicholas C. Smith, Michael Wallach
  • Nucleic acids encoding recombinant 56 and 82 kDa antigens from gametocytes of and their uses
    Patent number: 7423137
    Abstract: The present invention provides the recombinant cloning and sequencing of two of the major Eimeria maxima gametocyte antigens having molecular weights of 56 and 82 kDa and the expression of these recombinant antigens in an E. coli expression system using the plasmid pTrcHis. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen. The subject invention also provides two 30 kDa proteins and three 14 kDa proteins from Eimeria maxima gametocytes having at the N-terminal end the amino acid sequence described herein. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen and any of the aforementioned proteins.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: September 9, 2008
    Assignee: Abic Biological Laboratories Teva, Ltd.
    Inventors: Sabina I. Belli, Nicholas C. Smith, Michael Wallach